• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [18582 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-Heparin/Platelet Factor 4 antibody assey]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Anti-GD2 immunotherapy in patients with high risk neuroblastoma]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Annual Report 2010. German version.]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with deep vein thrombosis]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with carotid artery disease]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Angiographic profile of patients undergoing drug eluting stent implantation in Spain. Variability of off-label indications]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Analytic Hierarchy Process (AHP): pilot project to elicit patient preferences in the indication "depression"]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of tuberculosis isolation and prophylaxis techniques at a hospital level]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the use of simple cranium, chest and abdomen radiology in emergency hospital services]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the use of clinical protocols for monitoring the chronically ill in primary health care]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the status, systematic review and validation of a diagnostic algorithm for pulmonary thromboembolism (PTE) in the hospital emergency services of the Basque Health Service]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the scientific evidence on the effectiveness and efficiency of different kinds of hip prosthesis. Recommendations]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the evolution of main causes of mortality in 65 and older people in the Basque Country (1986-2001)]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the efficiency of the laboratory test in emergency care]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the efficacy, safety and efficiency of stabilisation of intervertebral discs using Discogel]
1998     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the efficacy of the treatments and costs of Alzheimer's disease in the Basque Country]
1996     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the cost-effectiveness of the non-mydriatic retinal camera for diabetic retinopathy]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the appropriateness of hospital admissions from emergencies]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the adequacy of diagnostic indications of the following application techniques of cerebral MR: MR spectroscopy, diffusion, gadolinum perfusion and cerebral functional-activation MR in advanced neurological diagnosis]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of telemedicine applications in the management-coordination of specialized and primary care. Appraisal of results and costs of pre-existing experiences (teleophthalmology)]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of surgical antibiotic prophylaxis]
2007     Andalusian Health Technology Assessment Area (AETSA) [Analysis of RET mutations to perform prophylactic thyroidectomy in individuals at risk for medullary thyroid cancer]
2011     Andalusian Health Technology Assessment Area (AETSA) [Analysis of health and socioeconomic factors influencing the progressive increase in frequentation of hospital emergency services]
2011     The Swedish Council on Health Technology Assessment (SBU) [Analysis of fetal DNA in maternal blood: non-invasive fetal diagnostic tests for blood group and sex determination]
2006     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Analysis of factors that can influence the levels of TSH in the neonatal period]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Analysis of clinical studies of medical devices]
2008     Andalusian Health Technology Assessment Area (AETSA) [Analysis of APC mutations to perform prophylactic colectomy in subjects at risk for colorectal cancer]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Analysis for healthcare safety management system]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis and review of protocols and quality standards in the diagnostic process for the detection of cervical cancer]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Analysis and development of preventive activities in primary care. Review of the preferential offer and its support software (PAP)]
2016     The Swedish Council on Health Technology Assessment (SBU) [Anal sphincter injuries]
2016     Basque Office for Health Technology Assessment (OSTEBA) [An image-guided system for liver surgery (CAScination)]
1998     Andalusian Health Technology Assessment Area (AETSA) [An evidence-based guideline on unstable angina management]
2015     Basque Office for Health Technology Assessment (OSTEBA) [An evaluation of the efficacy of psychosocial techniques (cognitive rehabilitation vs. psychoeducation) as an additional treatment to pharmacological treatment in bipolar disorder]
2014     Basque Office for Health Technology Assessment (OSTEBA) [An evaluation of intensity-modulated radiotherapy (IMRT)]
2007     Andalusian Health Technology Assessment Area (AETSA) [AmpliChip CYP450: Cytochrome P450 genotyping in psychiatric patients]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Amotosalen (Intercept) for the inactivation of pathogens for transfusion therapy]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]
2009     Committee for New Health Technology Assessment (CNHTA) [AMH]
1998     Basque Office for Health Technology Assessment (OSTEBA) [Ambulatory ultrasound in Basque country: current status, recommendations on its use and practice]
2009     Committee for New Health Technology Assessment (CNHTA) [Ambulatory esophageal multichannel impedence pH monitoring]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Alternatives to short stay psychiatric hospitalisation. Intensive ambulatory monitoring programmes]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alternatives to blood transfusion]
2015     Norwegian Institute of Public Health (NIPH) [Alternatives of plasma for transfusion to patients]
2015     Haute Autorite de sante (HAS) [Alternative(s) to 99mTc-sestamibi preoperative scintigraphy for the localization of hypersecreting parathyroid glands in the event of complete shortage of 99mTechnetium (99mTc)]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Alternative methods for the treatment of post-menopausal troubles]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Alprostadil for nonrevascularizable critical lower limb ischemia]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alpha1 antitrypsin]
2012     Andalusian Health Technology Assessment Area (AETSA) [Allomap genetic test for cardiac transplant rejection]
2009     Committee for New Health Technology Assessment (CNHTA) [Allo skin graft]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Allergic diseases: suggestions concerning organization of prevention, diagnostics and treatment (funded by DIHTA)]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Alirocumab for patients with hypercholesterolemia]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - addendum to commission A15-47]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alipogene tiparvovec - assessment according to §35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Alglucosidase alpha (Myozyme) for treatment of patients with late-onset Pompe disease]
2014     Andalusian Health Technology Assessment Area (AETSA) [Alglucosidase alfa (Myozyme ®) in late-onset Pompe disease]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab in multiple sclerosis]
2016     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab for multiple sclerosis]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alefacept (Amevive(R)) for the treatment of severe psoriasis]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small-cell lung cancer) - addendum to commission A17-19]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albutrepenonacog alfa - assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Albumin Dialysis and Molecular Adsorbent Recirculating System (MARS) in the treatment of liver failure]
2011     Haute Autorite de sante (HAS) [Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albiglutide - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2008     Committee for New Health Technology Assessment (CNHTA) [AGL gene, mutation[sequencing]]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Age-related macular degeneration: the role of current treatment strategies]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Aflibercept for age-related macular degeneration and central retinal vein occlusion]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) – benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Eylea) extension of approval: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (extension of approval) - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Addendum to Commission A14-32)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Advisability of expanding the Québec newborn blood screening program]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [Advantages of vestibular rehabilitation on the vestibular neuritis]
2008     Committee for New Health Technology Assessment (CNHTA) [Adenovirus, nested PCR]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to the final report A09-02 (benefit assessment of prasugrel)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-26 (empagliflozin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-21 (fingolimod)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-19 (mirabegron)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A14-14 (dimethyl fumarate)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-12 (canagliflozin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A14-05 (sofosbuvir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-44 (ipilimumab)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-37 (regorafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-35 (dabrafenib)]